The ability of disseminated cancer cells to evade the immune response is a critical step for efficient metastatic progression. Protection against an immune attack is often provided by the tumor microenvironment that suppresses and excludes cytotoxic CD8+ T cells. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive metastatic disease with unmet needs, yet the immunoprotective role of the metastatic tumor microenvironment in pancreatic cancer is not completely understood. In this study we find that macrophage-derived granulin contributes to cytotoxic CD8+ T cell exclusion in metastatic livers. Granulin expression by macrophages was induced in response to colony-stimulating factor-1. Genetic depletion of granulin reduced the formati...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease that can develop therap...
Monocytes and macrophages make up part of the innate immune system and provide one of the first defe...
Pancreatic ductal adenocarcinoma (PDAC) is an insidious disease with a low five-year survival rate. ...
Pancreatic ductal adenocarcinoma (PDAC) is a devastating metastatic disease for which better therapi...
Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immuno...
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic malignancies. PDAC bui...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant disease with a 5-year survival ra...
Despite modest improvements in survival in recent years, pancreatic adenocarcinoma remains a deadly ...
Immune evasion is indispensable for cancer initiation and progression, although its underlying mecha...
Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immuno...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease that can develop therap...
The survival rate for pancreatic ductal adenocarcinoma (PDAC) remains low. More therapeutic options ...
The high progression rate of Pancreatic Ductal Adenocarcinoma (PDAC) depends on intrinsic genetic an...
SummaryCancer-associated inflammation is thought to be a barrier to immune surveillance, particularl...
Cancer-associated inflammation plays a decisive role in restraining anti-tumor immunity, particularl...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease that can develop therap...
Monocytes and macrophages make up part of the innate immune system and provide one of the first defe...
Pancreatic ductal adenocarcinoma (PDAC) is an insidious disease with a low five-year survival rate. ...
Pancreatic ductal adenocarcinoma (PDAC) is a devastating metastatic disease for which better therapi...
Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immuno...
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic malignancies. PDAC bui...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant disease with a 5-year survival ra...
Despite modest improvements in survival in recent years, pancreatic adenocarcinoma remains a deadly ...
Immune evasion is indispensable for cancer initiation and progression, although its underlying mecha...
Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immuno...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease that can develop therap...
The survival rate for pancreatic ductal adenocarcinoma (PDAC) remains low. More therapeutic options ...
The high progression rate of Pancreatic Ductal Adenocarcinoma (PDAC) depends on intrinsic genetic an...
SummaryCancer-associated inflammation is thought to be a barrier to immune surveillance, particularl...
Cancer-associated inflammation plays a decisive role in restraining anti-tumor immunity, particularl...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease that can develop therap...
Monocytes and macrophages make up part of the innate immune system and provide one of the first defe...
Pancreatic ductal adenocarcinoma (PDAC) is an insidious disease with a low five-year survival rate. ...